Enliven Therapeutics, Inc. ( ELVN) - Key Metrics
ELVN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.49 | -$0.28 | -$0.28 |
| 2026Q1 | $0 | -$0.38 | -$0.31 | -$0.31 |
| 2025Q4 | $0 | -$0.52 | -$0.28 | -$0.28 |
| 2025Q3 | $0 | -$0.32 | -$0.21 | -$0.21 |
| 2025Q2 | $0 | -$0.49 | -$0.33 | -$0.33 |
ELVN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -25.89 |
| 2026Q1 | 0% | -25.79 |
| 2025Q4 | 0% | -8.56 |
| 2025Q3 | 0% | -15.99 |
| 2025Q2 | 0% | -10.23 |
ELVN
Price: $59.39
52 week price:
Earnings Per Share: -1.65 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 4.4 billion